Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

0:48Thestudy,publishedinthejournalJAMANetworkOpen,surveyed468formerprofessionalmalesoccerplayers.STO AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha




explore

author：hotspot    Page View：8393
UCB website -- health policy coverage from STAT
Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

advertisement

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested
Next article： BioMarin wins approval for gene therapy to treat hemophilia A